- Ezetimibe
] Results from the trial have provoked three large clinical-outcome trials. The results from these trials will be presented in the next three to four years. However, a March 30th, 2008 meeting of the ACC resulted in negative press for drugs like Zetia as Yale University Cardiologist Harlan Krumholz and concurring colleagues called into question the efficacy of such drugs. [cite news
url=http://www.businessweek.com/bwdaily/dnflash/content/mar2008/db20080331_704360.htm? |title=A Weak Prognosis for Vytorin and Zetia
author= Carey, J|publisher=Business Week|date=2008-03-31|accessdate=2008-04-01] Krumholz' statements maintained that such pharmaceuticals should not be the first or even second option for prescribing doctors. Definitive conclusions of the efficacy and safety of Zetia can be made such a time when the results of more substantial and comprehensive trials are released, such as the upcoming IMPROVE-IT Trial which has an enrollment of 18000 patients and will report results in 2012.Results of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial (ClinicalTrials.gov number, NCT00092677 [ClinicalTrials.gov] ) showed a potential increase in cancer in association with the use of these drugs together. (www.nejm.org September 2, 2008 (10.1056/NEJMe0807200). The actual significance has yet to be determined.
References
ee also
*
Ezetimibe/simvastatin
*Statin External links
* [http://www.zetia.com Zetia]
* [http://www.zetia.com/ezetimibe/zetia/consumer/product_information/pi/index.jsp U.S. Prescribing Information]
Wikimedia Foundation. 2010.
